|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
EP4091624A1
(en)
|
2013-03-15 |
2022-11-23 |
Protagonist Therapeutics, Inc. |
Hepcidin analogues and uses thereof
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA2949215C
(en)
|
2014-05-16 |
2023-03-14 |
Protagonist Therapeutics, Inc. |
.alpha.4.beta.7 integrin thioether peptide antagonists
|
|
SG10201810154WA
(en)
|
2014-07-17 |
2018-12-28 |
Protagonist Therapeutics Inc |
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
|
|
JP2017535527A
(ja)
|
2014-10-01 |
2017-11-30 |
プロタゴニスト セラピューティクス， インコーポレイテッド |
新規のα４β７ペプチド単量体及び二量体拮抗薬
|
|
WO2016054445A1
(en)
|
2014-10-01 |
2016-04-07 |
Protagonist Therapeutics, Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
GB2545898B
(en)
|
2015-12-21 |
2019-10-09 |
Sutura Therapeutics Ltd |
Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
|
|
CA3009834A1
(en)
|
2015-12-30 |
2017-07-06 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
CA3017926C
(en)
|
2016-03-23 |
2023-10-10 |
Protagonist Therapeutics, Inc. |
Methods for synthesizing .alpha.4.beta.7 peptide antagonists
|
|
WO2018022937A1
(en)
|
2016-07-27 |
2018-02-01 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
|
|
JP2020505352A
(ja)
*
|
2017-01-18 |
2020-02-20 |
プロタゴニスト セラピューティクス， インコーポレイテッド |
インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
GB2563875B
(en)
*
|
2017-06-28 |
2020-08-19 |
Sutura Therapeutics Ltd |
Improvements in drug delivery
|
|
EP3681900A4
(en)
|
2017-09-11 |
2021-09-08 |
Protagonist Therapeutics, Inc. |
OPIOID AGONIST PEPTIDES AND THEIR USES
|
|
WO2019157268A1
(en)
|
2018-02-08 |
2019-08-15 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
CA3104418A1
(en)
*
|
2018-07-12 |
2020-01-16 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
CN110015978B
(zh)
*
|
2019-04-29 |
2021-03-19 |
康化（上海）新药研发有限公司 |
O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
|
|
EP3993775A4
(en)
*
|
2019-07-01 |
2023-08-23 |
Valitor, Inc. |
HYDROPHILIC LINKERS FOR MULTIVALENT PEPTIDE CONJUGATES
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2020311395A1
(en)
*
|
2019-07-10 |
2022-02-03 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP3819307A1
(en)
*
|
2019-11-07 |
2021-05-12 |
CytoKi Pharma ApS |
Therapeutic derivatives of interleukin-22
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
SMT202500254T1
(it)
*
|
2020-01-15 |
2025-09-12 |
Janssen Biotech Inc |
Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
|
|
MX2022008740A
(es)
*
|
2020-01-15 |
2022-09-23 |
Janssen Biotech Inc |
Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MX2022016012A
(es)
*
|
2020-06-29 |
2023-03-10 |
Univ Washington |
Polipéptidos de unión al receptor de la il-23 humana.
|
|
EP4211468A4
(en)
|
2020-09-11 |
2024-10-09 |
Glympse Bio, Inc. |
DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
|
|
AU2021383828A1
(en)
*
|
2020-11-20 |
2023-07-06 |
Janssen Pharmaceutica Nv |
Compositions of peptide inhibitors of interleukin-23 receptor
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CA3226539A1
(en)
*
|
2021-07-14 |
2023-01-19 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor
|
|
JP2024525723A
(ja)
*
|
2021-07-14 |
2024-07-12 |
ヤンセン バイオテツク，インコーポレーテツド |
インターロイキン－２３受容体の二環式ペプチド阻害剤
|
|
KR20240034224A
(ko)
|
2021-07-14 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
인터류킨-23 수용체의 지질화된 펩티드 억제제
|
|
AU2022402440A1
(en)
|
2021-12-01 |
2024-05-30 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
US20250223627A1
(en)
*
|
2022-03-09 |
2025-07-10 |
Glympse Bio, Inc. |
Fluorogenic substrates for aminopeptidase detection in biofluids
|
|
CN114751962B
(zh)
*
|
2022-03-17 |
2023-11-07 |
北京大学 |
订书肽、其制备方法及其制药用途
|
|
WO2024003313A1
(en)
|
2022-06-30 |
2024-01-04 |
Sanofi |
New peptides as selective il-23 receptor antagonists
|
|
KR20250110326A
(ko)
*
|
2022-11-21 |
2025-07-18 |
얀센 파마슈티카 엔브이 |
고리형 펩타이드의 합성
|
|
EP4652180A2
(en)
*
|
2023-01-16 |
2025-11-26 |
Janssen Pharmaceutica NV |
Peptide inhibitors of interleukin-23 receptor
|
|
EP4652181A1
(en)
*
|
2023-01-16 |
2025-11-26 |
Janssen Pharmaceutica NV |
Polycyclic peptide inhibitors of interleukin-23 receptor
|
|
TW202440615A
(zh)
*
|
2023-01-16 |
2024-10-16 |
比利時商健生藥品公司 |
介白素－２３受體之肽抑制劑
|
|
KR20250139359A
(ko)
|
2023-01-31 |
2025-09-23 |
얀센 파마슈티카 엔브이 |
인터류킨-23 수용체의 결정질 펩티드 억제제의 제조 방법
|
|
CN121443624A
(zh)
*
|
2023-05-04 |
2026-01-30 |
西藏海思科制药有限公司 |
白介素-23受体的肽抑制剂制备及其用途
|
|
EP4471048A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
EP4471049A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
CN121794283A
(zh)
|
2023-09-08 |
2026-04-03 |
赛诺菲 |
作为选择性il-23受体抑制剂的新型肽
|
|
CN121909205A
(zh)
|
2023-09-08 |
2026-04-21 |
赛诺菲 |
作为选择性il-23受体抑制剂的新型肽
|
|
WO2026013260A1
(en)
|
2024-07-12 |
2026-01-15 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
WO2026057052A1
(zh)
*
|
2024-09-14 |
2026-03-19 |
深圳信立泰药业股份有限公司 |
一种il-23受体抑制剂及其制备方法和用途
|